By Timothy S. Donahue
Top Takeaways:
- U.S. Expansion: Japan Tobacco acquired CLEW’s U.S. assets from Nevcore Innovations, adding nicotine pouches to its portfolio.
- Established Distribution: CLEW is sold through outlets in 13 states, while JTI LIGGETT’s cigarette network reaches more than 160,000 stores.
- FDA Status: The acquisition includes a PMTA, but CLEW is not among the FDA’s 67 authorized nicotine pouch products.
Japan Tobacco is entering the U.S. nicotine pouch business just as Russia is taking control of its operations there.
On November 12, the company announced it acquired the U.S. assets of the nicotine pouch brand CLEW from Nevcore Innovations Inc., adding an established brand to its JTI LIGGETT portfolio. The transaction closed on November 10, and financial terms were not disclosed.
The purchase comes less than a week after Russian President Vladimir Putin ordered the temporary takeover of Japan Tobacco’s Russian subsidiaries, a move that threatens one of the company’s most profitable international markets.
As Nicotine Insider previously reported, Russia initially placed four JT manufacturing subsidiaries under the management of a Russian company on November 5. A subsequent decree expanded the intervention to three additional entities, bringing all seven of JT’s Russian businesses under temporary administration.
According to JT’s November 9 disclosure, Russia accounts for about 10% of consolidated revenue and 25% of adjusted operating profit. The company reported approximately ¥1.5 trillion in Russian assets, including ¥360 billion in cash and deposits.
The Russian intervention and CLEW acquisition are separate developments, and JT has not indicated that events in Russia influenced the U.S. purchase.
The CLEW transaction includes trademarks, intellectual property, product formulations, and a premarket tobacco product application (PMTA). The brand currently distributes through selected retail outlets in 13 U.S. states.
Idil Yasa, JTI’s regional president for the Americas, said the acquisition supports the company’s strategy to expand its U.S. business and to establish a presence in the nicotine pouch category.
The purchase follows JT’s approximately $2.4 billion acquisition of Vector Group in October 2024, which substantially expanded JT’s U.S. cigarette operations through Liggett and its brands, including Montego and Eagle.
JTI LIGGETT describes itself as the fourth-largest U.S. cigarette manufacturer, with a market share of more than 8% and products distributed through more than 160,000 retail stores. That network could offer opportunities for CLEW, although JT has not announced plans to distribute the brand through its existing cigarette retail channels.
JT already competes internationally in nicotine pouches through Nordic Spirit. CLEW provides its U.S. business with an established brand and retail presence in a market dominated by Philip Morris International’s ZYN, Altria’s on!, and British American Tobacco’s VELO.
However, CLEW faces a significant regulatory hurdle.
In June 2024, Nevcore announced that the FDA had accepted a PMTA submission for CLEW nicotine pouches. Acceptance means the application has entered the agency’s review process; it does not authorize marketing of the products.
As of November 12, the FDA’s public list included 67 authorized nicotine pouch products, including ZYN, on! and VELO offerings. CLEW was not among them. JT has not disclosed which CLEW products are covered by the application, their current review status, or whether additional submissions are planned.
The company said the acquisition would be financed with existing cash and would not materially affect its consolidated financial results in 2026.
The deal gives JT an immediate foothold in the U.S. nicotine pouch market as it faces significant uncertainty about its Russian business. Whether CLEW can secure FDA authorization and expand beyond its current retail footprint remains to be seen.
